Últimas noticias sobre KWESST Micro Systems (NASDAQ:KWE) Bolsa

KWESST Micro Systems

KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

KWESST Micro Systems Inc. - common stock, no R/S concurrent with offering

KWESST Micro Systems Inc

KraneShares Trust KraneShares CSI China Internet ETF

Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $319.65, a high estimate of $350.00, and a low estimate of $270.00. Marking an increase of 6.35%, the current average surpasses the previous average price target of $300.56. 
<img src="https://www.benzinga.com/files/images/story/2024/1734552034_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Monday.Com's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$302.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Lucky Schreiner</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>George Iwanyc</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$340.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Connor Murphy</td>
<td>Capital One</td>
<td>Announces</td>
<td>Overweight</td>
<td>$325.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$320.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$327.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Monday.Com. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Monday.Com compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Monday.Com's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Monday.Com's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MNDY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Monday.Com analyst ratings.</a>
<h2>Discovering Monday.Com: A Closer Look</h2>
Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.
<h3>Monday.Com's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Monday.Com showcased positive performance, achieving a revenue growth rate of 32.67% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Monday.Com's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -4.79%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.28%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Monday.Com's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.79%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Monday.Com's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MNDY

17 Analysts Assess Monday.Com: What You Need To Know

During the last three months, 4 analysts shared their evaluations of Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Treace Medical Concepts and provided 12-month price targets. The average target is $7.6, accompanied by a high estimate of $8.40 and a low estimate of $6.00. This upward trend is evident, with the current average reflecting a 6.0% increase from the previous average price target of $7.17.
<img src="https://www.benzinga.com/files/images/story/2024/1734552024_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Treace Medical Concepts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.40</td>
<td>$7.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$7.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Treace Medical Concepts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Treace Medical Concepts compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Treace Medical Concepts's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Treace Medical Concepts's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TMCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Treace Medical Concepts analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Treace Medical Concepts</h2>
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
<h3>Unraveling the Financial Story of Treace Medical Concepts</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Treace Medical Concepts displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 10.62%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Treace Medical Concepts's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -34.07%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Treace Medical Concepts's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -14.15%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.0%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Treace Medical Concepts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TMCI

Deep Dive Into Treace Medical Concepts Stock: Analyst Perspectives (4 Ratings)

Macro Economic Events

Economics

Federal Reserve

Powell Says It Might Take Another Year Or Two From Here To Get To 2%

8 analysts have shared their evaluations of MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $51.38, along with a high estimate of $55.00 and a low estimate of $43.00. Surpassing the previous average price target of $49.14, the current average has increased by 4.56%.
<img src="https://www.benzinga.com/files/images/story/2024/1734552013_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of MPLX among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MPLX. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MPLX compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for MPLX's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MPLX's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MPLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MPLX analyst ratings.</a>
<h2>Unveiling the Story Behind MPLX</h2>
MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.
<h3>Breaking Down MPLX's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: MPLX displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 2.28%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 37.14%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): MPLX's ROE excels beyond industry benchmarks, reaching 7.52%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): MPLX's ROA stands out, surpassing industry averages. With an impressive ROA of 2.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: MPLX's debt-to-equity ratio is below the industry average at 1.66, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MPLX

What Analysts Are Saying About MPLX Stock

Powell Says Housing Inflation Has Come Down Steadily,  Goods Inflation Has Returned To Pre-Pandemic Range Overall

Editor's Note: The spelling of Michael Saylor&#8217;s name has been corrected in the headline.
Financial market commentator Peter Schiff on Tuesday criticized Michael Saylor&#8217;s comparison of MicroStrategy Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) debt-financed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) buying strategy to Manhattan real estate.
What Happened: In an X post, Schiff disagreed with Saylor&#8217;s analogy. &#8220;Real estate generates rents, which can be used to service and repay debt. Bitcoin doesn&#8217;t generate any income to make interest or principal payments,&#8221; he argued.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It&#39;s wrong for <a href="https://twitter.com/saylor?ref_src=twsrc%5Etfw">@saylor</a> to compare his leveraged buying of <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> to investors borrowing money to purchase Manhattan real estate. Real estate generates rents, which can be used to service and repay debt. Bitcoin doesn&#39;t generate any income to make interest or principal payments.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1869116244714262623?ref_src=twsrc%5Etfw">December 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Spencer Hakimian, founder of hedge fund Tolou Capital Management, countered Schiff&#8217;s viewpoint, stating that, unlike the Manhattan real estate industry, Bitcoin doesn&#8217;t have any expenses or maintenance.
Schiff responded that rents from real estate exceed the expenses.
The city&#8217;s rental market contradicts national trends, with the top 50 markets experiencing 15 consecutive months of rent decreases. In October 2024, New York&#8217;s <a href="https://www.benzinga.com/real-estate/24/12/42256888/as-nyc-rents-hit-new-highs-85-of-residents-look-to-buy-elsewhere-heres-what-they-find">median asking rent</a> increased 1.7% year-on-year to $3,374, representing a 13.1% increase from pre-pandemic values. Manhattan&#8217;s median monthly rent stood at $4,750 as of this writing, according to Realtor.com.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42544639/moonpay-partners-with-element-wallet-to-boost-core-token-access-in-btcfi-ecosystem">MoonPay Partners With Element Wallet To Boost Core Token Access In BTCfi Ecosystem</a>
Why It Matters: This criticism comes after Saylor defended MicroStrategy&#8217;s Bitcoin acquisition strategy by equating it to Manhattan&#8217;s real estate industry. He said that <a href="https://www.benzinga.com/24/12/42524546/michael-saylor-counters-critics-who-label-microstrategys-bitcoin-play-ponzi-scheme-calls-it-similar-to-manhattans-real-estate-developers-using-debt-to-build-more-skyscrapers">just like developers in Manhattan issue more debt </a>to develop more real estate when its value goes up, MicroStrategy capitalizes on high returns from Bitcoin to buy more Bitcoin.
Schiff&#8217;s critique adds to the ongoing debate around MicroStrategy&#8217;s Bitcoin strategy. Earlier, he <a href="https://www.benzinga.com/24/11/42237876/peter-schiff-predicts-microstrategys-bankruptcy-due-to-bitcoin-investment-strategy">warned that the</a> company's commitment to repay a large sum of money to convertible note holders could be a potential risk if the price of Bitcoin falls sharply.
Well-known cryptocurrency analyst Willy Woo also <a href="https://www.benzinga.com/24/11/42228264/crypto-analyst-flags-convertible-debt-induced-liquidation-risk-to-michael-saylors-microstrategy">flagged the risk </a>associated with the firm&#8217;s convertible debt offerings, stating that if buyers do not convert to shares&nbsp;before maturity, MicroStrategy would be forced to sell Bitcoin to repay them.
Price Action:&nbsp; At the time of writing, Bitcoin was exchanging hands at $105,351.94, down 0.86% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>. 
Shares of MicroStrategy closed 5.41% lower at $ 386.42 during Tuesday&#8217;s regular session. The stock has a <a href="https://www.benzinga.com/quote/MSTR">consensus price target </a>of $449.5 based on the ratings of 12 analysts, with an average price target of $546.67 between&nbsp;Bernstein,&nbsp;TD Cowen, and&nbsp;Barclays.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42538636/pudgy-penguin-token-launches-at-2-billion-valuation-could-land-between-shiba-inu-and-dogecoin-trader-says">Pudgy Penguin Token Launches At $2 Billion Valuation, Could Land &#8216;Between Shiba Inu And Dogecoin,&#8217; Trader Says</a></li>
</ul>
Image via Flickr/ Gage Skidmore

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Bitcoin Is No Manhattan Real Estate, Peter Schiff Challenges MicroStrategy's Michael Saylor: 'BTC Doesn't Generate Any Income' (CORRECTED)

Powell Says Outlook Is Bright For Economy, Want To Keep Labor Market Pretty Close Where It Is; Says Job Creation Is A Little Below Level

Powell Says Core Inflation Coming Down To 2.5% Next Year, Would Be Significant Progress

Powell Says Committee Discussing Ways Tariffs Can Drive Inflation, Says Puts Fed In Place To Make A Careful Assessment Of Appropriate Policy Response To Tariffs; Says Many Factors Affect How Much Tariffs Will Go Into Consumer Inflation, Premature To Make Conclusion

Baird analyst Ben Kallo is reassessing the <a href="https://www.benzinga.com/electric-vehicles">electric vehicle landscape</a> in light of geopolitical uncertainty and policy changes. 
Here are two EV players attempting to navigate the turns ahead in 2025.
<h2 class="wp-block-heading">Tesla</h2>
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) remains a top pick with Baird emphasizing its long-term potential despite near-term volatility. The stock, up nearly 91% since the election, has momentum, Kallo says:
<ul>
<li>New Models: Upcoming vehicles, including the lower-cost &#8216;Model 2&#8217; and Cybertruck, promise to drive volume growth.</li>
<li>Cost Efficiencies: Falling production costs and increased factory utilization are expected to boost margins.</li>
<li>Regulatory Tailwinds: While the removal of the EV tax credit is a negative for the sector, Tesla's competitors are likely to feel the pinch more.</li>
<li>AI and Autonomy: Investments in full self-driving (FSD), Dojo compute, and the Optimus robot could redefine the EV market.</li>
</ul>
However, Tesla's valuation, geopolitical risks tied to its Shanghai operations, and potential delays in autonomy initiatives are points of caution. 
Kallo suggests buying on pullbacks, underlining Tesla's strong position as a market leader.
Read Also: <a href="https://benzinga.com/news/24/12/42515720/whats-going-on-with-rivian-rivn-stock">What&#8217;s Going On With Rivian (RIVN) Stock?</a>
<h2 class="wp-block-heading">Rivian</h2>
Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) faces a tougher road ahead, earning a downgrade to Neutral.
This downgrade reflects a challenging near-term outlook. Despite a strong brand and promising long-term potential, Kallo highlights several hurdles:
<ul>
<li>Demand Concerns: EV sales may fall short of expectations in 2025, dampening momentum.</li>
<li>Production Challenges: Limited ability to leverage fixed costs due to lower production volumes.</li>
<li>Few Catalysts: With the Volkswagen joint venture finalized and DOE funding secured, Rivian lacks clear drivers for growth next year.</li>
</ul>
While Kallo remains optimistic about Rivian's R2 lineup and its long-term opportunity. But skepticism around near-term profitability and margins led to the Neutral rating.
<h2 class="wp-block-heading">The Big Picture</h2>
As the EV market faces headwinds from policy uncertainty and evolving global dynamics, Tesla continues to dominate while Rivian, though promising, has more to prove in the near term. 
For investors, it's a tale of two trajectories—one accelerating confidently, the other stuck in neutral.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42548657/tesla-design-chief-says-ev-giant-was-looking-to-create-future-version-of-nycs-yellow-cabs-with-gold-cybercab-it-feels-right">Tesla Design Chief Says EV Giant Was Looking To Create &#8216;Future Version&#8217; Of NYC&#8217;s Yellow Cabs With Gold Cybercab: &#8216;It Feels Right&#8217;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Tech

RIVN

TSLA

Tesla Remains A Top EV Stock Pick, Rivian Faces Roadblocks: Analyst

Two men from Rochester, New York, met their end after developing a "rare fungal lung infection" linked to using bat guano, or feces, as fertilizer for growing cannabis for their personal use.
The University of Rochester detailed the cases in a <a href="https://academic.oup.com/ofid/article/11/12/ofae711/7917418">report</a> published in Open Forum Infectious Diseases, warning that "exposure to bat guano among cannabis growers appears to be a recent trend that can lead to histoplasmosis cases and outbreaks." Histoplasmosis is a lung infection caused by inhaling spores of the Histoplasma fungus. It is also known as the &#8220;cave disease.&#8221;
What Happened: The first man (59), bought his guano online to use as fertilizer for his cannabis plants. The second man (64), was intending to fertilize his cannabis plants with the bat poop he found in his attic following a heavy bat infestation.
The 59-year-old, a heavy tobacco smoker who had emphysema and arthritis, was hospitalized for respiratory failure after experiencing weight loss, a sore throat and difficulty swallowing over six weeks. A biopsy confirmed histoplasmosis.
The second man, who had vascular disease, reported a "heavy bat infestation" in his attic where he regularly inspected the thick layer of guano, which he intended to use as fertilizer for his cannabis plants, <a href="https://www.livescience.com/health/viruses-infections-disease/bat-poop-used-to-grow-cannabis-kills-2-in-new-york-in-unusual-cases">reported</a> Live Science. He was hospitalized for low sodium levels, chronic coughing and weight loss after initially being treated for histoplasmosis.
<h2 class="wp-block-heading">Histoplasmosis: Rare But Deadly </h2>
Histoplasmosis is often misdiagnosed or diagnosed too late, which naturally can exacerbate its severity. Symptoms include fever, muscle aches and chest pain. In severe cases, the infection can spread to the brain and spinal cord, causing meningitis. The disease affects an estimated 1 to 2 per 100,000 people annually in the U.S., though researchers suggest the prevalence may be higher due to underreporting or misdiagnosis.
The authors of the report stressed the urgent need for public awareness, particularly as <a href="https://www.benzinga.com/topic/cannabis-legalization">cannabis legalization</a> and the promotion of bat guano fertilizers grow. "Commercial biofertilizers containing bat guano should be tested for [the fungus] before reaching the market," they wrote. "If testing is not feasible, risk mitigation strategies should be implemented.
"The association between histoplasmosis cases and outbreaks with environmental disturbances, particularly in the presence of bat and bird droppings, is well recognized," said the researchers.
They also noted that climate change and bat migration patterns could be adding to an increase in Histoplasma infections. While bats are primary carriers of the fungus, bird droppings can also contribute to its spread.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42488355/bird-flu-spreads-to-cats-possibly-horses-as-officials-signal-no-plans-to-authorize-vaccination">Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination</a></li>
</ul>
Photo: Danny Ye/Shutterstock.com

Cannabis

Bat Poop Kills 2 Cannabis Farmers In New York From 'Rare' Fungal Infections

Powell Says Higher Inflation Is Probably Biggest Factor For New Projections; Moving Sideways On 12-Month Inflation

Investors with a lot of money to spend have taken a bullish stance on RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for RH.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 25%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $87,050, and 5 are calls, for a total amount of $235,910.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $160.0 to $470.0 for RH during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for RH's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of RH's whale trades within a strike price range from $160.0 to $470.0 in the last 30 days. 
<h3>RH Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734551138_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$49.7</td>
<td>$49.0</td>
<td>$49.0</td>
<td>$440.00</td>
<td>$98.0K</td>
<td align="right">132</td>
<td align="right">20</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$76.0</td>
<td>$73.2</td>
<td>$76.0</td>
<td>$470.00</td>
<td>$53.2K</td>
<td align="right">186</td>
<td align="right">7</td>
</tr>
<tr>
<td>RH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.7</td>
<td>$6.4</td>
<td>$6.4</td>
<td>$415.00</td>
<td>$32.0K</td>
<td align="right">78</td>
<td align="right">52</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.7</td>
<td>$17.5</td>
<td>$17.7</td>
<td>$430.00</td>
<td>$31.8K</td>
<td align="right">701</td>
<td align="right">32</td>
</tr>
<tr>
<td>RH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$28.8</td>
<td>$28.8</td>
<td>$28.8</td>
<td>$300.00</td>
<td>$28.8K</td>
<td align="right">176</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About RH</h3>
RH is a luxury furniture and lifestyle retailer operating in the $134 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 19 restaurant locations. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade by expanding abroad, with its World of RH digital platform (highlighting offerings outside of home furnishings), and with offerings in bespoke furniture, architecture, media, and more.
<h3>RH's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 458,435, the RH's price is up by 0.55%, now at $414.0. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 98 days.</li>
</ul>
<h3>What Analysts Are Saying About RH</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $442.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $425. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on RH, maintaining a target price of $435. 
&#x2A; An analyst from Loop Capital has decided to maintain their Hold rating on RH, which currently sits at a price target of $450. 
&#x2A; Reflecting concerns, an analyst from Stifel lowers its rating to Buy with a new price target of $420. 
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Market Perform rating for RH, targeting a price of $480. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for RH with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Behind the Scenes of RH's Latest Options Trends

Whales with a lot of money to spend have taken a noticeably bearish stance on Qualcomm.
Looking at options history for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) we detected 24 trades.
If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 58% with bearish.
From the overall spotted trades, 15 are puts, for a total amount of $770,801 and 9, calls, for a total amount of $376,265.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $180.0 for Qualcomm, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Qualcomm stands at 1771.79, with a total volume reaching 2,158.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Qualcomm, situated within the strike price corridor from $105.0 to $180.0, throughout the last 30 days.
<h3>Qualcomm 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734551133_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.75</td>
<td>$4.65</td>
<td>$4.65</td>
<td>$165.00</td>
<td>$111.1K</td>
<td>5.6K</td>
<td align="right">484</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$19.25</td>
<td>$18.75</td>
<td>$18.75</td>
<td>$155.00</td>
<td>$88.1K</td>
<td>2.1K</td>
<td align="right">113</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$7.45</td>
<td>$7.4</td>
<td>$7.45</td>
<td>$140.00</td>
<td>$83.4K</td>
<td>365</td>
<td align="right">149</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$30.4</td>
<td>$29.4</td>
<td>$29.45</td>
<td>$180.00</td>
<td>$64.7K</td>
<td>470</td>
<td align="right">22</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.8</td>
<td>$8.7</td>
<td>$8.8</td>
<td>$155.00</td>
<td>$64.1K</td>
<td>2.1K</td>
<td align="right">96</td>
</tr>
</tbody>
</table>

<h3>About Qualcomm</h3>
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
Having examined the options trading patterns of Qualcomm, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Qualcomm Standing Right Now?</h3>
<ul>
<li>With a volume of 3,282,009, the price of QCOM is up 0.09% at $158.07. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 42 days.</li>
</ul>
<h3>Professional Analyst Ratings for Qualcomm</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $183.33333333333334.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $160. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Qualcomm, targeting a price of $210. 
&#x2A; Reflecting concerns, an analyst from Melius Research lowers its rating to Hold with a new price target of $180.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Qualcomm with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

QCOM

Looking At Qualcomm's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALB, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Albemarle.
This isn't normal.
The overall sentiment of these big-money traders is split between 0% bullish and 81%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $65,484, and 9 are calls, for a total amount of $540,108.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $150.0 for Albemarle over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Albemarle stands at 1298.12, with a total volume reaching 1,164.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Albemarle, situated within the strike price corridor from $80.0 to $150.0, throughout the last 30 days.
<h3>Albemarle Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734551128_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.9</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$95.00</td>
<td>$142.8K</td>
<td align="right">245</td>
<td align="right">0</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$35.7</td>
<td>$35.5</td>
<td>$35.5</td>
<td>$80.00</td>
<td>$78.1K</td>
<td align="right">10</td>
<td align="right">29</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.75</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$150.00</td>
<td>$75.0K</td>
<td align="right">567</td>
<td align="right">201</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.75</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$150.00</td>
<td>$75.0K</td>
<td align="right">567</td>
<td align="right">101</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.45</td>
<td>$12.4</td>
<td>$12.45</td>
<td>$110.00</td>
<td>$37.4K</td>
<td align="right">103</td>
<td align="right">207</td>
</tr>
</tbody>
</table>

<h3>About Albemarle</h3>
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.
After a thorough review of the options trading surrounding Albemarle, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Albemarle's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 867,338, the ALB's price is down by -3.59%, now at $94.05. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 56 days.</li>
</ul>
<h3>Professional Analyst Ratings for Albemarle</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $103.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Neutral rating on Albemarle with a target price of $103. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Albemarle, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Albemarle

<a href="https://www.gov.ca.gov/2024/12/18/governor-newsom-takes-proactive-action-to-strengthen-robust-state-response-to-bird-flu/#:~:text=What%20you%20need%20to%20know,ongoing%20cross%2Dagency%20response%20efforts" title="https://www.gov.ca.gov/2024/12/18/governor-newsom-takes-proactive-action-to-strengthen-robust-state-response-to-bird-flu/#:~:text=What%20you%20need%20to%20know,ongoing%20cross%2Dagency%20response%20efforts">https://www.gov.ca.gov/2024/12/18/governor-newsom-takes-proactive-action-to-strengthen-robust-state-response-to-bird-flu/#:~:text=What%20you%20need%20to%20know,ongoing%20cross%2Dagency%20response%20efforts</a>

Health Care

General

NVAX

CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts

Pudgy Penguins (CRYPTO: PENGU) newly launched token has found its way into established media, coinciding with a <a href="https://www.benzinga.com/24/12/42496442/if-you-invested-1000-in-pudgy-penguins-nfts-at-mint-heres-how-much-youd-have-today">rally on Wednesday</a>.
What Happened: In a FOX Business interview on Tuesday, Robinhood CEO Vlad Tenev expressed skepticism about meme coins, calling them &#8220;distractions.&#8221; He noted how easy it is to create such tokens, gain liquidity and launch them globally.
The interviewer specifically <a href="https://x.com/GeneralPudgy/status/1869233192965976376">asked</a> about PENGU, which debuted at a $2.3 billion valuation and peaked at $90 million in trading volume within the first hour. Tenev did not mention PENGU specifically.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42411112/shiba-inu-pepe-or-bonk-ranking-reddits-most-popular-meme-coins">Shiba Inu, Pepe Or Bonk? Ranking Reddit&#8217;s Most Popular Meme Coins</a>
Trader Notes: Prominent crypto trader Ansem reacted to a tweet by analyst Byzantine General, revealing a new long position on PENGU. 
The analyst described PENGU&#8217;s chart as &#8220;interesting,&#8221; noting that a continued price rally could fill the wick—a move worth watching closely.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is starting to look interesting. Imagine the seething if this pumps straight back up to fill the wick.<a href="https://twitter.com/search?q=%24PENGU&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PENGU</a> <a href="https://t.co/Nwz604JdEw">pic.twitter.com/Nwz604JdEw</a>
&mdash; Byzantine General (@ByzGeneral) <a href="https://twitter.com/ByzGeneral/status/1869410857484202040?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another trader, Leshka.eth, highlighted PENGU&#8217;s $2 billion valuation and the fact that over 70% of airdrops have already been claimed. 
Leshka emphasized the token&#8217;s resilience, <a href="https://x.com/leshka_eth/status/1869431593213042792">stating</a>: "This token survived $600,000,000 of sell pressure within 24 hours only -50% drawdown from the top."
Price Action: Over the past 24 hours, PENGU has surged 15%, outperforming Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>), both of which saw 4% drops during the same period.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42223340/bitcoin-meme-coins-to-go-through-7-stages-of-the-bull-run-between-now-and-march-trader-says">Bitcoin, Meme Coins To Go Through 7 Stages Of The Bull Run Between Now And March, Trader Says</a></li>
</ul>
Image: Shutterstock

$DOGE

$SHIB

Pudgy Penguins PENGU Token Extends Rally, Outperforms Dogecoin, Shiba Inu On Wednesday

ProShares UltraPro Short QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQQQ#NASDAQ">SQQQ</a>), which offers leveraged inverse exposure to the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), gained 3% to $28.95 Wednesday afternoon as the Federal Reserve <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">delivered a dovish tone during its December meeting</a>.
SQQQ, designed to rise when the Nasdaq-100 falls, benefits from bearish sentiment toward growth-oriented technology stocks.
What Happened: The Fed lowered the federal funds rate by 25 basis points to a range of 4.25%-4.5%, marking the third consecutive rate cut in 2023. 
However, its updated projections suggest fewer cuts in 2025, signaling persistently higher borrowing costs. This fueled concerns that tech stocks, which are sensitive to interest rates, may struggle under tighter monetary conditions.
Additionally, the Fed raised inflation expectations for 2025, projecting headline PCE inflation at 2.5%. Elevated inflation could pressure future earnings, further weighing on growth stocks.
As rate-sensitive tech valuations recalibrate, traders might turn to SQQQ to capitalize on market volatility.
Read Also: <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">Fed Slashes Interest Rates By 0.25% As Predicted: December Dot Plot Flags Only 2 Potential Cuts In 2025</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SQQQ has a 52-week high of $74.80 and a 52-week low of $27.54.

SQQQ

Why Nasdaq-100 Inverse ETF SQQQ Is Moving

Powell Says To Cut Further After This Point, Looking For Further Progress On Inflation And Strength In Labor Market

Powell Says The 'Extent And Timing' Language Shows We Are At Or Near Point Of Being Appropriate To Slow Rate Cuts; Says The Slower Pace Of Rate Cuts Reflects Expectation Of Higher Inflation But Sees Ourselves As Still On Track To Continue To Cut

KWESST Micro Systems (TSE:KWE) has released an update. KWESST Micro Systems Inc. has announced a share consolidation that will convert ten pre-cons...

KWESST Announces Strategic Share Consolidation

19:50 EDT Kwesst Micro Systems (KWE) Inc. trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving...

Kwesst Micro Systems Inc. trading halted, news pending

KWESST Micro Systems (TSE:KWE) has released an update. KWESST Micro Systems has successfully ramped up the production of its ARWEN cartridges, outs...

KWESST Boosts Production and Secures Funding

KWESST Micro Systems (TSE:KWE) has released an update. KWESST Micro Systems Inc. is set to raise approximately $3.5 million through a public offeri...

KWESST Micro Systems Plans $3.5 Million Public Offering

KWESST announces issuance of shares in payment of certain debts

KWESST Micro Systems (TSE:KWE) has released an update. KWESST Micro Systems plans to issue 119,047 common shares at a discounted price to settle a ...

KWESST Issues Shares for Debt Settlement

KWESST Micro Systems (TSE:KWE) has released an update. KWESST Micro Systems Inc. successfully closed a CAD$3.4 million private placement with an in...

KWESST Secures CAD$3.4 Million in Private Placement

KWESST Micro Systems receives extension to meet Nasdaq price requirement

KWESST Micro Systems files to sell 8.5M common shares for holders

KWESST Micro Systems (TSE:KWE) has released an update. KWESST Micro Systems Inc. has reported no known operational changes that would explain recen...

Comments

KWESST Micro Systems

Noticias

Últimas noticias sobre KWESST Micro Systems (NASDAQ:KWE) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL